Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,104,702
  • Shares Outstanding, K 687,550
  • Annual Sales, $ 5,711 M
  • Annual Income, $ 700,160 K
  • 60-Month Beta 0.65
  • Price/Sales 2.29
  • Price/Cash Flow 11.46
  • Price/Book 1.69
Trade GRFS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.35
  • Number of Estimates 2
  • High Estimate 0.35
  • Low Estimate 0.35
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.62 +25.03%
on 09/21/20
20.05 -2.59%
on 10/15/20
+3.37 (+20.85%)
since 09/18/20
3-Month
15.18 +28.66%
on 09/04/20
20.11 -2.88%
on 07/21/20
-0.63 (-3.12%)
since 07/20/20
52-Week
13.40 +45.75%
on 03/16/20
25.73 -24.10%
on 02/21/20
-1.27 (-6.11%)
since 10/18/19

Most Recent Stories

More News
Thinking about buying stock in Staffing 360 Solutions, Electrameccanica Vehicles, Grifols SA, Newage Beverage, or Norwegian Cruise Line?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, SOLO, GRFS, NBEV, and NCLH.

GRFS : 19.53 (+2.47%)
NCLH : 17.08 (+3.83%)
STAF : 1.3500 (+3.05%)
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

- - - - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

and , /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor...

MSFT : 214.65 (+0.20%)
GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Grifols Procleix Panther System with Automation Ready Technology (ART) receives FDA Approval

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
Grifols launches new 3-mL (900-IU) vial for high-potency HyperRAB® (rabies immune globulin [human])

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS : 19.53 (+2.47%)
ZTS : 159.69 (-0.19%)
People Who Have Recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines,...

GRF : 7.03 (+0.62%)
GRFS : 19.53 (+2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 20.18
1st Resistance Point 19.86
Last Price 19.53
1st Support Level 19.23
2nd Support Level 18.92

See More

52-Week High 25.73
Fibonacci 61.8% 21.02
Fibonacci 50% 19.56
Last Price 19.53
Fibonacci 38.2% 18.11
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar